Railpen has raised its takeover proposal for IP Group PLC (LSE:IPO), offering shareholders a mix of

Shares in IP Group PLC (LSE:IPO) rose 9% to 53.5p on Monday after the company reported net asset val

Metsera Inc. (NASDAQ: MTSR - Get Free Report) has been given a consensus rating of "Hold" by the eig

Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to r

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its

Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing

Metsera was the target of a bidding war by pharma giants. The company has an innovative obesity drug

On this episode of Stock Movers with Lisa Mateo: - Metsera (MTSR) shares tank in premarket trading a

Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc

Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech

Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acqui

Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part o

The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven tre

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 1.5% on Monday.

Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal

Shares in Novo Nordisk NOVOb.CO rose in early trade on Monday, after the Wegovy-maker on Saturday dr

13F filings this week will reveal hedge fund and institutional moves, offering insight into smart mo

Bagsværd, Denmark, 8 November 2025 – Novo Nordisk today confirms that it does not intend to make an

Pfizer prevails over rival Novo Nordisk after an unusual bidding war for the weight-loss startup.

Revised transaction values Metsera at up to $86.25 per share Metsera's Board of Directors unanimousl

Pfizer has submitted a sweetened bid for obesity drug developer Metsera , as its fight against rival

Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you